Prestige Consumer Healthcare (PBH) AI Stock Analysis

• Market Cap: $2.94B
• Dividend Yield: N/A
• Average Volume (3M): 407.76K
• Price to Earnings (P/E): 14.4
• Beta (1Y): 0.32
• Revenue Growth: 0.63%
• EPS Growth: 4.23%
• Country: US
• Employees: 600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 1.07
• Shares Outstanding: 49,214,172
• 10 Day Avg. Volume: 389,042
• 30 Day Avg. Volume: 407,759
• PEG Ratio: 7.62
• Price to Book (P/B): 2.33
• Price to Sales (P/S): 3.76
• P/FCF Ratio: 17.56
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $77.75
• Price Target Upside: 26.71% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 4.51
• Revenue Forecast (FY): $1.10B

• Rating: 66 Neutral
• Price Target: $66.00 ▲(7.56% Upside)

Prestige Consumer Healthcare's overall stock score is driven by its strong financial performance and reasonable valuation. However, the bearish technical indicators and challenges highlighted in the earnings call, such as declining revenue and supply constraints, weigh on the score. The company's strategic focus on e-commerce growth and market share expansion in the dental category are positive factors that could support future performance.

Positive Factors

E-commerce Growth

Sustained e-commerce growth indicates a strong digital presence and adaptability to consumer trends, supporting long-term revenue expansion.

DenTek Market Share Expansion

Significant market share gains in the dental category enhance competitive positioning and potential for sustained revenue growth.

Cash Flow Generation

Strong cash flow generation supports financial flexibility, enabling strategic investments and shareholder returns.

Negative Factors

Revenue Decline

Declining revenue poses challenges to growth, potentially impacting long-term profitability and market competitiveness.

Clear Eyes Supply Constraints

Supply constraints can lead to lost sales and reduced market share, affecting long-term brand strength and revenue.

Uncertain Retailer Inventory Patterns

Variable order patterns create revenue unpredictability, complicating planning and potentially impacting financial stability.

Prestige Consumer Healthcare Business Overview & Revenue Model

Company Description

Prestige Consumer Healthcare (PBH) is a leading global company specializing in over-the-counter (OTC) healthcare products. The company operates in various sectors including pain relief, cold and allergy, personal care, and foot care. PBH's core offerings include well-known brands such as TheraGun, Dramamine, and Chloraseptic, among others, which cater to a wide range of consumer health needs.

How the Company Makes Money

PBH generates revenue primarily through the sale of its branded OTC healthcare products in both retail and e-commerce channels. The company leverages its established brand portfolio and extensive distribution network to reach consumers effectively. Key revenue streams include direct sales to major retail chains, pharmacies, and online platforms. Additionally, PBH benefits from partnerships with various retailers for promotional activities and shelf space, which enhance product visibility and sales. The company also invests in marketing and innovation to develop new products and improve existing ones, driving further revenue growth.

Prestige Consumer Healthcare Financial Statement Overview

Summary

Prestige Consumer Healthcare demonstrates solid financial health with strong profitability and cash flow metrics. While revenue growth has faced challenges, the company maintains efficient operations and a balanced financial structure. Continued focus on revenue expansion could further enhance financial performance.

Income Statement

Prestige Consumer Healthcare shows strong profitability with a consistent gross profit margin around 56-57% and a net profit margin close to 19% in the TTM. However, the revenue growth rate has been negative recently, indicating a potential challenge in expanding sales. The EBIT and EBITDA margins are healthy, reflecting efficient cost management.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of around 0.56 in the TTM, showing a balanced approach to leveraging. Return on Equity is solid at approximately 11.8%, indicating effective use of shareholder funds. The equity ratio is stable, suggesting a sound financial structure.

Cash Flow

Cash flow performance is robust with a notable free cash flow growth rate of 10.1% in the TTM. The operating cash flow to net income ratio is strong, indicating good cash generation relative to earnings. The free cash flow to net income ratio is nearly 1, highlighting efficient cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.11B	1.14B	1.13B	1.13B	1.09B	943.37M
Gross Profit	623.49M	634.46M	624.45M	625.29M	620.65M	547.47M
EBITDA	354.43M	361.99M	373.86M	14.19M	351.61M	310.38M
Net Income	200.84M	214.60M	209.34M	-82.31M	205.38M	164.68M
Balance Sheet
Total Assets	3.44B	3.40B	3.32B	3.35B	3.67B	3.43B
Cash, Cash Equivalents and Short-Term Investments	119.11M	97.88M	46.47M	58.49M	27.18M	32.30M
Total Debt	47.88M	1.04B	1.14B	1.37B	1.51B	1.51B
Total Liabilities	1.62B	1.57B	1.66B	1.91B	2.09B	2.07B
Stockholders Equity	1.82B	1.83B	1.66B	1.45B	1.58B	1.36B
Cash Flow
Free Cash Flow	255.45M	243.29M	239.38M	221.93M	250.28M	213.36M
Operating Cash Flow	263.44M	251.51M	248.93M	229.72M	259.92M	235.61M
Investing Cash Flow	-18.16M	-17.45M	-20.11M	-11.58M	-256.51M	-22.24M
Financing Cash Flow	-176.58M	-182.07M	-241.01M	-185.85M	-7.57M	-279.42M

Prestige Consumer Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 61.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Negative. The current price of 61.36 is below the 20-day moving average (MA) of 61.53, below the 50-day MA of 63.11, and below the 200-day MA of 76.21, indicating a bearish trend. The MACD of -0.77 indicates Positive momentum. The RSI at 46.18 is Neutral, neither overbought nor oversold. The STOCH value of 30.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBH.

Prestige Consumer Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MCK	72 Outperform	$105.01B	26.29	―	0.36%	17.23%	66.17%
HSIC	69 Neutral	$8.48B	22.14	11.39%	―	3.51%	29.65%
PBH	66 Neutral	$2.94B	14.40	12.05%	―	0.63%	4.23%
CAH	65 Neutral	$46.41B	29.49	―	1.04%	4.37%	28.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GRDN	47 Neutral	$1.80B	-19.71	-97.70%	―	―	―
OMI	38 Underperform	$269.94M	―	-184.47%	―	-37.09%	-2639.44%

Prestige Consumer Healthcare Corporate Events

Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results

Prestige Consumer Healthcare Inc. is a prominent company in the consumer healthcare sector, known for its extensive range of over-the-counter healthcare products, including popular brands like Clear Eyes® and Monistat®. The company operates primarily in North America and international markets, focusing on brand-building and maintaining a strong financial profile.

Prestige Consumer Healthcare’s Earnings Call Highlights Growth and Challenges

Prestige Consumer Healthcare’s recent earnings call conveyed a generally positive sentiment, emphasizing strong growth in e-commerce and effective cost management. The company highlighted its successful market share expansion in the dental category, although it acknowledged challenges such as supply constraints affecting Clear Eyes and declining revenue in key categories. Strategic investments in marketing and acquisitions are anticipated to bolster future growth.

Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results

On November 6, 2025, Prestige Consumer Healthcare reported its financial results for the second quarter and first half of fiscal 2026, ending September 30, 2025. The company achieved revenues of $274.1 million in Q2, slightly below the previous year’s $283.8 million due to supply constraints in the Eye & Ear Care category. Despite this, the company exceeded its sales and earnings expectations, driven by strategic brand-building and share repurchases. The fiscal 2026 revenue outlook remains unchanged, but the adjusted diluted EPS outlook has been updated to the higher end of the previous range. The company continues to focus on rebuilding supply chain capacity for Clear Eyes and anticipates improvements in the second half of the fiscal year.

The most recent analyst rating on (PBH) stock is a Hold with a $71.00 price target. To see the full list of analyst forecasts on Prestige Consumer Healthcare stock, see the PBH Stock Forecast page.

Prestige Consumer Healthcare’s Cautious Earnings Call Outlook

During the recent earnings call, Prestige Consumer Healthcare expressed a cautious sentiment. Despite strong performances in the International segment and an expansion in gross margin, challenges in the eye care supply chain and retail order volatility have led to a lowered revenue outlook. The acquisition of Pillar5 is a strategic move to address these issues, but the immediate outlook remains cautious.

Prestige Consumer Healthcare’s Q1 Earnings and Strategic Moves

Prestige Consumer Healthcare Inc. is a leading company in the consumer healthcare sector, known for its diverse portfolio of over-the-counter healthcare products, including well-known brands such as Clear Eyes and Monistat, with operations spanning across the U.S., Canada, and international markets.

Prestige Consumer Healthcare Acquires Pillar5 Pharma for Expansion

On August 4, 2025, Prestige Consumer Healthcare Inc. announced a definitive agreement to acquire Pillar5 Pharma Inc., a leading Canadian sterile ophthalmic manufacturer and current supplier of Clear Eyes, from ANJAC SAS for CAD 150 million. This acquisition is part of Prestige’s strategy to expand eye care production capacity and address supply chain challenges, with the transaction expected to close in the third quarter of fiscal 2026. The company also reported a decline in first-quarter fiscal 2026 revenue to $249.5 million due to supply constraints in the eye care category, although international segment growth and improved gross margins were noted. The acquisition of Pillar5 is anticipated to secure long-term supply chain capacity and support Prestige’s growth opportunities, despite a revised revenue outlook for fiscal 2026.

The most recent analyst rating on (PBH) stock is a Hold with a $90.00 price target. To see the full list of analyst forecasts on Prestige Consumer Healthcare stock, see the PBH Stock Forecast page.